Polymyositis & Immune-Mediated Necrotizing Myopathy
The inflammatory myopathies have undergone a major reclassification over the past two decades. Historical “polymyositis” was a broad diagnostic category encompassing many patients who, with modern serologic and histopathologic tools, are now recognized as having immune-mediated necrotizing myopathy (IMNM), antisynthetase syndrome, inclusion body myositis, or muscular dystrophy. Studies using updated classification criteria have reclassified up to 78% of historical polymyositis cases into other entities—most commonly IMNM. True polymyositis, defined by endomysial CD8+ T-cell invasion of non-necrotic fibers expressing MHC-I, is now considered rare and by many experts a diagnosis of exclusion. Alongside this reclassification, IMNM and antisynthetase syndrome have emerged as distinct, well-characterized entities with specific antibody profiles, pathologic signatures, and treatment implications. This article reviews the current understanding of these overlapping conditions, with emphasis on diagnosis, antibody-guided management, and evolving treatment strategies.
Bottom Line
- Polymyositis is vanishing: With modern myositis-specific antibodies (MSAs) and updated histopathologic criteria, the majority of cases previously diagnosed as polymyositis have been reclassified as IMNM, antisynthetase syndrome, or IBM; true polymyositis is now considered rare and a diagnosis of exclusion
- Antisynthetase syndrome: Defined by anti-aminoacyl-tRNA synthetase antibodies (anti-Jo-1 most common); classic triad of myositis, interstitial lung disease (ILD), and inflammatory arthritis; mechanic’s hands, Raynaud phenomenon, and fever are characteristic; ILD is the major driver of morbidity and mortality
- IMNM subtypes: Anti-HMGCR (70%) often associated with statin exposure but can occur without statins, very high CK, IVIg-responsive; anti-SRP (10%) presents with severe weakness, cardiac involvement, and treatment resistance; seronegative (~20%) requires muscle biopsy for diagnosis
- Pathology is key: PM shows endomysial CD8+ T-cell invasion of non-necrotic fibers with MHC-I upregulation; IMNM shows scattered myofiber necrosis with minimal inflammation, macrophage predominance, and variable complement deposition; antisynthetase syndrome shows perimysial pathology with perifascicular atrophy
- Treatment: Corticosteroids remain first-line for most patients; IVIg is particularly effective in IMNM (especially anti-HMGCR); rituximab is valuable for refractory cases; anti-SRP IMNM often requires aggressive combination immunotherapy; antisynthetase syndrome treatment must address both muscle and lung disease
- Cancer screening: Required for all IMNM patients (especially anti-HMGCR and seronegative subtypes); antisynthetase syndrome does not appear to carry elevated cancer risk
The Evolving Concept of Polymyositis
The original Bohan and Peter criteria (1975) defined polymyositis based on symmetric proximal weakness, elevated CK, myopathic EMG findings, and inflammatory muscle biopsy—without accounting for differences in histopathology, antibody profiles, or the existence of antisynthetase syndrome and IMNM. These criteria predated the discovery of MSAs and were unable to distinguish the now-recognized subtypes of idiopathic inflammatory myopathy (IIM). Consequently, the “polymyositis” category became a heterogeneous collection that included patients with IMNM, antisynthetase syndrome, dermatomyositis sine dermatitis, IBM, and even some muscular dystrophies (particularly dysferlinopathy and calpainopathy).
Modern reclassification studies consistently demonstrate that 70–80% of historical polymyositis cases are reclassified when MSA testing and updated histopathologic criteria are applied. The 2017 EULAR/ACR classification criteria for IIM and the 119th and 239th ENMC international workshops have progressively refined the nosology, adding IMNM and nonspecific myositis as separate categories. Some authorities now argue that polymyositis should be abandoned entirely as a primary diagnosis, while others retain it as a rare diagnosis of exclusion requiring strict histopathologic criteria—endomysial invasion of non-necrotic, MHC-I-expressing fibers by CD8+ T cells—in the absence of identifiable MSAs, rimmed vacuoles, or features of other IIM subtypes.
When to Suspect a Diagnosis Other Than Polymyositis
- Positive MSA test (anti-HMGCR, anti-SRP, anti-Jo-1, or other antisynthetase antibodies) → reclassify accordingly
- Skin findings, even subtle (heliotrope rash, Gottron papules, V-sign) → dermatomyositis or dermatomyositis sine myositis
- Finger flexor or quadriceps-predominant weakness, especially in patients >45 years → evaluate for IBM (rimmed vacuoles, p62/TDP-43 aggregates)
- Mechanic’s hands, ILD, nonerosive arthritis, Raynaud phenomenon → antisynthetase syndrome
- Very high CK (>5000 U/L) with minimal inflammation on biopsy → IMNM
- Family history of myopathy, childhood onset, slowly progressive weakness → consider muscular dystrophy (dysferlinopathy, FSHD, LGMD)
- Statin exposure with persistent CK elevation after discontinuation → anti-HMGCR IMNM
Antisynthetase Syndrome
Overview and Clinical Features
Antisynthetase syndrome (ASyS) is defined by the presence of antibodies against aminoacyl-tRNA synthetases, enzymes critical for protein synthesis. Eight antisynthetase antibodies have been identified, each targeting a different aminoacyl-tRNA synthetase and conferring a somewhat distinct clinical phenotype. The 273rd ENMC International Workshop (2024) established updated classification criteria that prioritize the presence of a high-confidence antisynthetase antibody plus at least one core feature (ILD, myositis, or inflammatory arthritis) for a “definite” diagnosis. ASyS does not appear to carry an increased risk of malignancy relative to the general population, distinguishing it from dermatomyositis.
The classic clinical presentation includes some or all components of the following triad and associated features:
- Myositis: Symmetric proximal weakness developing over weeks to months, with elevated CK; severity varies by antibody subtype (highest with anti-Jo-1, lowest with anti-PL-12 and anti-KS)
- Interstitial lung disease: The most important determinant of morbidity and mortality; affects 70–100% of patients; may precede or occur independently of myositis; ranges from nonspecific interstitial pneumonia (NSIP) to organizing pneumonia (OP) to usual interstitial pneumonia (UIP)
- Inflammatory arthritis: Nonerosive, often involving the small joints of the hands; can mimic rheumatoid arthritis
- Mechanic’s hands: Hyperkeratotic, fissured skin over the lateral and palmar aspects of the fingers and hands; a hallmark finding though not always present
- Raynaud phenomenon: Present in 20–60% of patients
- Fever: Unexplained fevers may accompany disease flares
Antisynthetase Antibodies
| Antibody | Target | Frequency | Myositis | ILD Severity | Key Features |
|---|---|---|---|---|---|
| Anti-Jo-1 | Histidyl | Most common (~60–70% of ASyS) | Severe | Moderate | Highest muscle involvement; severe arthritis; mechanic’s hands; best prognosis overall |
| Anti-PL-7 | Threonyl | ~10–15% | Moderate | Severe | Severe ILD; heliotrope rash may occur (overlap with DM); Raynaud; worse survival than Jo-1 |
| Anti-PL-12 | Alanyl | ~5–10% | Mild | Severe | ILD-predominant; minimal muscle involvement; ILD may precede myositis by years; worse survival; possible esophageal involvement |
| Anti-EJ | Glycyl | ~5% | Moderate | Severe | Severe ILD; arthritis; Raynaud; mechanic’s hands |
| Anti-OJ | Isoleucyl | Rare | Moderate | Severe | Severe ILD; less joint involvement |
| Anti-KS | Asparaginyl | Rare | Mild | Severe | ILD-predominant; mild rash; minimal myositis |
| Anti-Ha | Tyrosyl | Very rare | Mild | Mild | Arthritis; mechanic’s hands; mild overall phenotype |
| Anti-Zo | Phenylalanyl | Very rare | Mild | Mild | Arthritis; Raynaud; mechanic’s hands; mild phenotype |
Pathology of Antisynthetase Syndrome
Muscle biopsy in ASyS shares features with dermatomyositis but has distinguishing characteristics. Perimysial pathology is prominent, with perimysial fragmentation, alkaline phosphatase staining, and perivascular inflammation. Perifascicular atrophy can occur but MxA expression—a hallmark of dermatomyositis—is much less prominent. MHC-I upregulation and membrane attack complex deposition are seen on the sarcolemma, particularly in the perifascicular region. The type II interferon pathway, rather than type I, may be preferentially involved.
Management of Antisynthetase Syndrome
Treatment must address both myositis and ILD, with ILD driving long-term prognosis. Corticosteroids are first-line (prednisone 0.75–1 mg/kg/day), with early initiation of a steroid-sparing agent. For ILD-predominant disease, mycophenolate or rituximab are preferred; the RECITAL trial (2023) showed comparable efficacy between rituximab and cyclophosphamide for CTD-ILD with a better safety profile for rituximab. Methotrexate is avoided due to pulmonary toxicity risk. For myositis-predominant disease, methotrexate, azathioprine, or mycophenolate are options, with IVIg as add-on for refractory weakness. Rituximab is effective in refractory cases, particularly MSA-positive patients with ILD. Serial PFTs (FVC, DLCO) every 3–6 months and HRCT at baseline are essential for monitoring.
Immune-Mediated Necrotizing Myopathy
Overview
IMNM is characterized by acute or subacute proximal weakness with markedly elevated CK (often >5000 U/L, sometimes in the range of rhabdomyolysis >10,000 U/L), myofiber necrosis with minimal endomysial inflammation on biopsy, and autoantibodies against HMGCR (~70%) or SRP (~10%). Approximately 20% of IMNM patients are seronegative, requiring muscle biopsy confirmation. IMNM accounts for approximately 20% of all IIM cases and represents the largest proportion of cases reclassified from historical polymyositis.
Anti-HMGCR Immune-Mediated Necrotizing Myopathy
Anti-HMGCR antibodies target 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis and the pharmacologic target of statins. Key features include:
- Statin association: Approximately 60–67% of patients have prior statin exposure; however, one-third are statin-naive, indicating that statin exposure is neither necessary nor sufficient for disease development
- Distinguishing from statin myotoxicity: In statin-induced toxic myopathy, CK normalizes within 2–4 weeks of statin discontinuation and anti-HMGCR antibodies are absent; in anti-HMGCR IMNM, CK remains elevated or rises after statin withdrawal and the antibody is positive
- CK levels: Characteristically very high (often 5000–50,000 U/L); CK correlates with disease activity and antibody titers more reliably than in other IIMs, making it useful for monitoring treatment response
- Age distribution: Older patients (>50 years) are more likely to have had statin exposure; younger patients tend to have more severe, refractory disease requiring aggressive treatment
- Malignancy risk: Possible increased risk, particularly in patients >60 years; cancer screening is recommended
- Prognosis: IVIg-responsive in the majority; less than half of patients recover normal strength within 2 years, and only about two-thirds reach that level within 4 years
Anti-SRP Immune-Mediated Necrotizing Myopathy
Anti-SRP antibodies target the signal recognition particle, a cytoplasmic ribonucleoprotein complex essential for protein translocation to the endoplasmic reticulum. Anti-SRP IMNM is a more severe and treatment-resistant form of the disease:
- Severity: Severe proximal weakness with frequent neck weakness, dysphagia, and respiratory insufficiency; muscle atrophy may develop early
- Cardiac involvement: Myocarditis and arrhythmias reported in a significant minority; ECG and echocardiography should be considered at baseline and during flares
- ILD: Mild interstitial lung disease may occur, though less prominent than in antisynthetase syndrome
- Malignancy risk: Does not appear to be elevated above the general population
- Treatment resistance: Poor response to corticosteroid monotherapy; typically requires aggressive, early combination immunotherapy; less IVIg-responsive than anti-HMGCR IMNM
- Prognosis: Worse than anti-HMGCR IMNM; severe limb weakness, neck weakness, dysphagia, and muscle atrophy are more frequently observed; neurologic outcomes are generally poorer
Comparison of IMNM Subtypes
| Feature | Anti-HMGCR | Anti-SRP | Seronegative |
|---|---|---|---|
| Frequency in IMNM | ~70% | ~10% | ~20% |
| Statin association | 60–67%; can occur without statins | None | None |
| CK levels | Very high (often >10,000 U/L) | Very high | Elevated, variable |
| Weakness severity | Moderate to severe | Severe; neck, bulbar involvement | Variable |
| Cardiac involvement | Rare | Myocarditis, arrhythmias | Rare |
| ILD | Absent | Mild, occasional | Absent |
| Cancer risk | Possibly elevated (especially age >60) | Not elevated | Elevated; screening recommended |
| IVIg responsiveness | Good; often effective as monotherapy | Limited; combination therapy needed | Variable |
| Prognosis | Better; ~67% reach normal strength by 4 years | Worse; treatment-resistant, early atrophy | Intermediate; depends on biopsy severity |
Pathology
Polymyositis
The definitive histopathologic hallmark of polymyositis is endomysial CD8+ cytotoxic T-cell invasion of non-necrotic muscle fibers expressing MHC-I on their sarcolemma, reflecting an HLA-restricted, antigen-specific, cell-mediated immune response (though the target antigens remain unknown). There is no perifascicular atrophy (distinguishing from DM and ASyS) and no rimmed vacuoles or protein aggregates (distinguishing from IBM). Notably, most biopsies showing this pattern ultimately prove to be IBM rather than true polymyositis.
Immune-Mediated Necrotizing Myopathy
The pathologic hallmark of IMNM is scattered necrotic and regenerating muscle fibers in the absence of significant endomysial inflammatory infiltrate. Key features include:
- Necrosis: Scattered necrotic fibers at various stages—early necrosis, myophagocytosis (macrophage invasion of necrotic fibers), and regenerating basophilic fibers
- Minimal inflammation: Sparse inflammatory infiltrate, predominantly macrophages (CD68+); absence of the prominent CD8+ T-cell endomysial invasion seen in polymyositis
- MHC-I: Variable and faint sarcolemmal expression, much less prominent than in polymyositis or dermatomyositis
- Complement deposition: Membrane attack complex (C5b-9) may be detected on the sarcolemma of non-necrotic fibers and small blood vessels, though this is variable and not specific
- No perifascicular atrophy or tubuloreticular inclusions in endothelium (distinguishes from dermatomyositis)
- Chronic changes: In longstanding disease, fiber size variation, increased endomysial connective tissue, and fatty replacement may be prominent
Diagnostic Pitfalls in Inflammatory Myopathy
- Muscular dystrophies (especially dysferlinopathy, calpainopathy, FSHD) can show inflammation on biopsy and be misdiagnosed as polymyositis; genetic testing should be considered when MSAs are negative and clinical features are atypical
- Not all myopathies with inflammation on biopsy are inflammatory myopathies—secondary inflammation occurs in dystrophies, metabolic myopathies, and toxic myopathies
- Dermatomyositis sine dermatitis (adermatopathic DM) lacks skin findings and may be erroneously diagnosed as polymyositis if only the Bohan and Peter criteria are applied
- IBM is the most common misdiagnosis when CD8+ T-cell invasion of non-necrotic fibers is found—always evaluate for rimmed vacuoles, cytoplasmic inclusions (p62, TDP-43), and the characteristic clinical pattern of finger flexor and quadriceps weakness
- In patients with statin exposure and elevated CK, failure of CK to normalize within 2–4 weeks after statin discontinuation should prompt anti-HMGCR antibody testing rather than a diagnosis of simple statin myotoxicity
- A normal CK does not exclude inflammatory myopathy, particularly in chronic disease with extensive atrophy, juvenile dermatomyositis, or amyopathic dermatomyositis
Diagnostic Evaluation
Serologic Testing
MSA testing is the single most important advance in inflammatory myopathy diagnosis. A comprehensive panel should be ordered in all suspected IIM patients. Anti-HMGCR and anti-SRP testing is essential; positive results in the appropriate clinical context may obviate muscle biopsy. Anti-Jo-1 is included in most panels, but non-Jo-1 antisynthetase antibodies (PL-7, PL-12, EJ, OJ, KS, Ha, Zo) require extended panels. Dermatomyositis antibodies (anti-Mi-2, anti-MDA-5, anti-TIF1-γ, anti-NXP-2, anti-SAE) and myositis-associated antibodies (anti-Ro52, anti-U1RNP, anti-PM/Scl) should be included. When MSAs are positive, the antibody profile guides prognosis, cancer screening, and treatment. When MSAs are negative, muscle biopsy, EMG, and MRI become critical for accurate classification.
Additional Workup
| Test | Purpose | Key Points |
|---|---|---|
| Serum CK | Disease activity marker | Most sensitive and specific serum enzyme; very high in IMNM (>5000–50,000 U/L); may be normal in chronic disease or amyopathic DM; correlates with activity in HMGCR IMNM; AST/ALT elevation without elevated GGT suggests muscle source |
| EMG | Confirm myopathy; guide biopsy | Fibrillation potentials (active disease); short-duration, low-amplitude MUAPs; does not differentiate IIM subtypes; may be unnecessary if CK is markedly elevated |
| Muscle MRI | Detect edema/inflammation; guide biopsy | STIR hyperintensity suggests active disease; T1 fatty replacement suggests chronic damage; does not reliably differentiate IIM subtypes (except IBM distribution) |
| Muscle biopsy | Definitive classification | Open biopsy preferred (larger sample); select mildly weak muscle; request CD3, CD8, CD68, CD20, MHC-I/II, and MAC stains; essential when MSAs are negative |
| Chest CT (HRCT) | ILD screening | Mandatory in all antisynthetase syndrome; consider in anti-SRP IMNM; NSIP and OP are the most common patterns |
| PFTs (FVC, DLCO) | Quantify and monitor ILD | Baseline in all ASyS and overlap syndromes; serial monitoring every 3–6 months; decline in DLCO may precede radiographic changes |
| ECG/Echocardiography | Cardiac involvement | Particularly important in anti-SRP IMNM; consider in all IIM subtypes with cardiac symptoms |
| Cancer screening | Exclude paraneoplastic etiology | Age-appropriate screening in all IIM; CT chest/abdomen/pelvis at diagnosis; heightened surveillance in anti-HMGCR, seronegative IMNM, and DM (especially anti-TIF1-γ); repeat within 3 years if initially negative |
Treatment
General Principles
Treatment relies on immunomodulatory and immunosuppressive therapy. If treatment is ineffective, the original diagnosis should be reconsidered to exclude IBM, muscular dystrophies, and metabolic myopathies. In patients with longstanding weakness and atrophy who show partial recovery despite optimal therapy and CK normalization, MRI showing fatty atrophy without edema and EMG without spontaneous activity suggest chronic, irreversible muscle injury.
Corticosteroids
Prednisone remains first-line for most IIM subtypes, increasingly used as a bridge to steroid-sparing agents:
- Dosing: 0.75–1 mg/kg/day (typically 60 mg daily); in severe cases, IV methylprednisolone 1 g/day for 3–5 days followed by oral taper
- Taper: Improvement begins within 2–4 months, plateaus by 4–6 months; taper by 10 mg every 4 weeks until 20 mg/day, then 2.5–5 mg every 4 weeks until 10 mg/day, then 1–2 mg every 4 weeks
- CK in IMNM: CK declines more rapidly than strength improves; a rising CK during taper signals relapse
- In other IIM subtypes: Base treatment decisions on clinical examination rather than CK alone
IVIg
IVIg has FDA-label indication for dermatomyositis and is a cornerstone of IMNM treatment. Dosing is 2 g/kg divided over 2–5 days, repeated monthly for at least 3 months, then tapered. In anti-HMGCR IMNM, many patients respond to IVIg monotherapy as first-line treatment. In anti-SRP IMNM, IVIg is less effective alone and is typically combined with corticosteroids and other immunosuppressants. Side effects include infusion reactions, headache, and rare complications (aseptic meningitis, renal dysfunction, thrombotic events).
Steroid-Sparing Immunosuppressants
| Agent | Dosing | Onset | Best For | Key Considerations |
|---|---|---|---|---|
| Methotrexate | 7.5–25 mg/week (oral or SC); coadminister folic acid 1 mg/day | Weeks to months | PM, DM, myositis-predominant IIM | Avoid in ASyS with ILD (pulmonary toxicity risk); teratogenic; stomatitis, hepatotoxicity |
| Azathioprine | 2–3 mg/kg/day | 4–8 months | All IIM subtypes | Check TPMT before starting; idiosyncratic flu-like reaction in ~10% within 3 weeks (requires permanent discontinuation); slow onset |
| Mycophenolate mofetil | 1–3 g/day (divided doses) | 3–6 months | ASyS with ILD; DM | Preferred for ILD-predominant ASyS; well tolerated; GI upset; teratogenic |
| Tacrolimus | 0.1–0.2 mg/kg/day | 1–3 months | ASyS; refractory IIM | Relatively rapid onset; monitor levels, renal function, blood pressure; widely used in Asia for IIM |
| Rituximab | 750 mg/m² ×2 doses (2 weeks apart); or 375 mg/m² weekly ×4; repeat every 6–18 months | Weeks to months | Refractory IMNM; ASyS with ILD; MSA-positive IIM | ~62% response rate in refractory IMNM; effective for ILD; small risk of PML (low, mostly with combination immunosuppression) |
| Cyclophosphamide | 0.5–1 g/m² IV monthly | 1–3 months | Severe refractory ILD | Reserved for severe refractory ILD; significant toxicity (hemorrhagic cystitis, infertility, malignancy); RECITAL showed rituximab is comparable with fewer side effects |
Treatment by IMNM Subtype
Antibody-Guided Treatment Approach in IMNM
- Anti-HMGCR IMNM:
- Discontinue statins immediately; statins should be permanently avoided
- IVIg 2 g/kg monthly is often effective as first-line monotherapy
- If CK does not decline after 2–3 cycles, add corticosteroids and/or a steroid-sparing agent
- Younger patients and those with severe weakness may need early combination therapy (IVIg + corticosteroids + rituximab or methotrexate)
- Monitor CK closely—it serves as a reliable surrogate for disease activity and antibody titers
- Taper IVIg gradually once CK normalizes and strength stabilizes (e.g., reduce to 1 g/kg monthly, then extend intervals)
- Consider bempedoic acid (a liver-specific lipid-lowering agent) as a safe alternative for dyslipidemia management
- Anti-SRP IMNM:
- Aggressive early combination immunotherapy is recommended given poor response to monotherapy
- Typically: corticosteroids + IVIg + a steroid-sparing agent (rituximab, mycophenolate, or azathioprine)
- Rituximab may be considered early in the disease course for refractory cases
- Monitor for cardiac involvement (ECG, echocardiography)
- Physical therapy is essential to mitigate early muscle atrophy
- Seronegative IMNM:
- Muscle biopsy is required for diagnosis
- Treatment follows general IMNM principles; corticosteroids with IVIg
- Cancer screening is particularly important given elevated malignancy risk
Emerging Therapies
- Efgartigimod (FcRn inhibitor): Restored muscle function in a humanized IMNM mouse model; phase 2/3 trial (NCT05523167) in DM, IMNM, and ASyS is underway
- CD19 CAR T-cell therapy: Efficacy demonstrated in refractory ASyS, juvenile DM, and IMNM in case series; CABA-201 phase 1/2 trial (NCT06154252) enrolling
- JAK inhibitors: Promising in refractory DM; limited data in IMNM and ASyS
- Complement inhibitors: Zilucoplan trial in IMNM did not meet primary endpoint, suggesting complement may not be the primary pathogenic driver
Monitoring and Prognosis
Monitoring Strategy
- Clinical assessment: Muscle strength testing (MRC scale, MMT-8) and functional assessments every 4–8 weeks during active treatment; less frequently once stable
- CK levels: Every 2–4 weeks during active treatment; particularly valuable in IMNM where CK correlates with disease activity; a rising CK during taper heralds relapse
- Pulmonary function: FVC and DLCO every 3–6 months in ASyS or documented ILD; decline in DLCO may precede radiographic changes
- Imaging: Muscle MRI (STIR for activity, T1 for chronic changes); HRCT chest for ILD progression
- Laboratory: CBC, hepatic/renal function per immunosuppressant; TPMT genotype before azathioprine; drug levels for calcineurin inhibitors
- Infection prophylaxis: TMP-SMX for PJP in chronic immunosuppression; screen for latent TB and hepatitis B/C before rituximab
- Bone health: DEXA if prednisone expected >3 months; calcium and vitamin D supplementation; bisphosphonates for osteoporosis
Prognosis by Antibody Type
| Condition | Prognosis | Key Prognostic Factors |
|---|---|---|
| Polymyositis (true) | Generally responsive to immunotherapy; rare entity | Must exclude IBM (which has poor treatment response); malignancy risk lower than DM but higher than general population |
| ASyS (anti-Jo-1) | Best prognosis among ASyS subtypes; responds to treatment | ILD severity; earlier diagnosis (Jo-1 patients diagnosed sooner due to prominent myositis); 5-year survival >90% in most series |
| ASyS (non-Jo-1) | Worse survival than Jo-1; ILD-predominant | Anti-PL-7 and anti-PL-12 associated with severe, early ILD and worse outcomes; Black patients have more severe ILD |
| IMNM (anti-HMGCR) | ~67% recover normal strength by 4 years; IVIg-responsive | Age at onset (younger patients more refractory); CK normalization predicts good outcome; prone to relapse, requiring prolonged treatment |
| IMNM (anti-SRP) | Poorest among IMNM subtypes; severe, treatment-resistant | Early muscle atrophy; cardiac involvement; less than half recover normal strength within 2 years; often requires lifelong immunotherapy |
| IMNM (seronegative) | Intermediate; variable course | Elevated malignancy risk; biopsy severity; response to initial immunotherapy |
Key Differentiators: When Active Disease vs. Chronic Damage
- Active disease: Elevated CK; STIR hyperintensity on MRI; fibrillation potentials on EMG; clinical weakness with ongoing decline; responds to immunotherapy escalation
- Chronic damage: Normal or near-normal CK; T1 fatty replacement on MRI without STIR hyperintensity; no abnormal spontaneous activity on EMG; stable weakness and atrophy despite treatment; immunotherapy unlikely to produce further improvement
- Distinguishing active disease from chronic damage is essential to avoid unnecessary immunosuppression and its attendant side effects in patients with irreversible muscle injury
- In patients on long-term corticosteroids who develop new or worsening proximal weakness, consider steroid myopathy as an alternative to disease relapse—MRI (no STIR signal) and EMG (no spontaneous activity) help differentiate
References
- Salajegheh MK, Amato AA. Idiopathic inflammatory myopathies. Continuum (Minneap Minn) 2025;31(5):1385–1408.
- Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017;76(12):1955–1964.
- Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol 2020;16(12):689–701.
- Suh J, Amato AA. Management of immune-mediated necrotizing myopathy. Muscle Nerve 2024;70(2):166–172.
- Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 2016;87(10):1038–1044.
- Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in Black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford) 2017;56(6):999–1007.
- Mammen AL, Amato AA, Dimachkie MM, et al. Zilucoplan in immune-mediated necrotizing myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol 2023;5(2):e67–e76.
- Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 2023;11(1):45–54.
- Aggarwal R, Charles-Schoeman C, Schessl J, et al. Trial of intravenous immune globulin in dermatomyositis. N Engl J Med 2022;387(14):1264–1278.
- Pinal-Fernandez I, Munoz-Braceras S, Casal-Dominguez M, et al. Pathological autoantibody internalisation in myositis. Ann Rheum Dis 2024;83(11):1549–1560.
- Mammen AL. Paraneoplastic myopathies. Handb Clin Neurol 2024;200:327–332.
- Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65(2):314–324.
- Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease—a case series with follow-up. N Engl J Med 2024;390(8):687–700.
- Tanboon J, Uruha A, Stenzel W, Nishino I. Where are we moving in the classification of idiopathic inflammatory myopathies? Curr Opin Neurol 2020;33(5):590–603.
- Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012;64(12):4087–4093.